As I see it

Share this article:
Many were waiting to see if and when the new FDA commissioner would make a significant difference in the agency's defensive, stonewalling posture.

A sign came in August, when Andrew von Eschenbach took the step of writing a letter to the editor of the Washington Post, defending the FDA from critical reports about its expenditure of $13 million on retention bonuses for senior employees supposedly about to quit for higher-paid jobs, at a time when the agency has been pleading insufficient funds to intercept contaminated imports.

The letter seemed to say that this wasn't a case of fat cats getting fatter. Rather, he said, over 90% of the $13 million went directly to the agency's docs and scientists. Only 9% went to members of the senior executive service and other managers.

He criticized a Post article that “mischaracterized the many contributions of two senior executives who received bonuses.” One of these was Margaret Glavin, who reportedly received a bonus that was one-eighth of her salary. The commissioner said she “established the FDA's Office of Counterterrorism Policy and Planning and has received two Presidential Rank awards.” OCI director Terry Vermillion got $23,000 but “founded the FDA's Office of Criminal Investigations and has led more than 4,600 national and international criminal investigations.”

While von Eschenbach's unusual step was not enough to deter the GAO from launching a wide investigation into whether the federal executives bonus program is being generally misused, it did show a refreshing willingness to get out ahead of a controversy. If the FDA is returning to its former policy of openness, everyone will welcome it. However, this will require reallocation of large resources to its communications areas, so don't hold your breath!

Dickinson is editor of Dickinson's FDA Webview (

Share this article:
You must be a registered member of MMM to post a comment.

Next Article in As I See It

Email Newsletters

MM&M Future Leaders

Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 


Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in As I See It

As I See It: Patient Centricity

As I See It: Patient Centricity

A patient who is diagnosed earlier and receives the most efficacious treatment is the least expensive

As I See It: FDA's social-media moves

As I See It: FDA's social-media moves

FDA has insisted that its antique regulations can address every new promotional challenge

As I See It: FDA and marketing materials

As I See It: FDA and marketing materials

The more clarity that FDA provides, the more confident companies can be in their medical communications